(Press-News.org) A direct comparison between the experimental psychedelic drug psilocybin and a standard SSRI antidepressant shows similar improvement of depressive symptoms, but that psilocybin offers additional longer-term benefits.
The comparison, between psilocybin (the active ingredient in “magic mushrooms”) and the SSRI escitalopram gave similar long-term improvements in depressive symptoms over a 6-month period, however patients taking psilocybin also reported better psychosocial functioning including experiencing a greater sense of meaning in life and psychological connectedness.
The work is presented for the first time at the ECNP Congress in Milan. A related paper will appear in the peer-reviewed journal Lancet eClinicalMedicine1 to coincide with the conference presentation (see details below). Lead researcher Mr Tommaso Barba (PhD candidate from Imperial College, London) said:
“This is the first work to compare the long-term effects of these two drugs in the context of overall well-being, not just freedom from depression. In previous work we had found that both treatments led to comparable improvements in alleviating symptoms of depression at the 6-week mark, such as sadness and negative emotions. However, this work shows that psilocybin outperformed escitalopram in several measures of well-being, meaning in life, work and social functioning. These results appeared to be maintained over a 6-month follow-up period. In addition, in previous work* we had found that psilocybin also improves sexual drive, in contrast to SSRIs which tend to lower libido in many patients. So overall it seems psilocybin might give additional positive mental health benefits.”
SSRI drugs (selective serotonin reuptake inhibitors), such as Prozac, Paxil and Zoloft, are one of the main types of drugs used to treat depression. However, around a third of patients don’t respond to SSRI treatment, so for them psilocybin may offer an alternative, although this was not studied in this trial.
Tommaso Barba continued:
“SSRIs work well, but not for everyone. They are also associated with some side effects. However this work implies that psilocybin generally seems to offer a real alternative, and perhaps additional benefits, to people who are worried about taking conventional antidepressants”.
The researchers, from Imperial College in London, undertook a 6-month study (phase 2, double-blind, randomised controlled trial) with 59 patients with moderate to severe depression. 30 were treated with a single dose of psilocybin, 29 patients were given a six-week course of escitalopram. Each group received similar psychological support of around 20 hours in total. Both groups showed significant improvement in depressive symptoms, even up to 6 months after treatment (the researchers stopped monitoring at 6 months). However those given psilocybin reported greater improvements in social functioning and psychological connectedness, with large effect sizes.
Co-first author Dr David Erritzoe, Clinical Director and Deputy Head of the Centre for Psychedelic Research, Imperial College, London, commented:
“This is important because improving connectedness and having greater meaning in life can significantly enhance a person's quality of life and long-term mental health. The study suggests that psilocybin therapy might be a more holistic treatment option for depression, addressing both the symptoms of depression and overall well-being. This could make a substantial difference in the overall happiness and daily activities of those suffering from depression, providing a more joined-up approach to mental health treatment”.
The researchers note that the patients were only treated for 6 weeks, and that many of the patients received additional treatments over the 6-month follow up.
Dr Erritzoe cautioned:
“Psilocybin is still an experimental drug; it has not yet been approved for general use. It is administered in highly controlled and protected environments: these precautions are not found in recreational psychedelic use, which is known for having unpredictable and potentially harmful effects, especially for vulnerable people struggling with mental health issues”.
Commenting, Johan Lundberg (Adjunct Professor of Psychiatry at the
Department of Clinical Neuroscience, Karolinska Institute, Stockholm) said:
“This report is an important attempt to compare the clinical value of psilocybin compared to a state-of-the-art treatment of major depressive disorder. The results come with several caveats, including the lack of a non-inferiority analysis and failure to report other interventions given during the follow-up period. That said, as a hypothesis generating piece it may benefit the field substantially. For now, we don’t know if psilocybin will be approved for the treatment of major depression, but if so, it won’t be for everyone. Some future patients might prefer psychedelic treatment over SSRI, but some patients may be intimidated by the dramatic alterations in perception and confrontations with challenging emotions that psychedelic drugs promote”.
This is an independent comment, Professor Lundberg was not involved in this work.
Notes:
Publication details: Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial. In press at Lancet eClinicalMedicine. Authors: David Erritzoe, Tommaso Barba, Kyle T. Greenway, Roberta Murphy, Jonny Martell, Bruna Giribaldi, Christopher Timmermann, Ashleigh Murphy-Beiner, Michelle Baker Jones, David Nutt, Brandon Weiss, and Robin Carhart-Harris. Paper reference 10.1016/j.eclinm.2024.102799
See Psychedelic experiences linked with improved sexual function | Imperial News | Imperial College London END
Milan, Italy: Around 80% of women suffer from “baby blues” after the birth of their child. Normally this is a brief period of feeling down which disappears in a few days. But around 1 woman in 7 develops postpartum depression; this is a more serious depression which can affect how mothers bond with their baby and can have long-term consequences. These women seem unable to regulate the negative emotions which can follow giving birth.
Now a group of European Reesearchers have found that in healthy pregnant women activity in a specific area deep in the brain is linked to regulation of negative ...
LOS ANGELES – Among patients with early-stage breast cancer treated with adjuvant endocrine therapy (AET), symptoms related to sexual health were associated with decreased adherence to treatment in Black women, according to results presented at the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held September 21-24, 2024.
Patients with hormone receptor-positive breast cancer are commonly given endocrine therapy—treatments that block estrogen signaling in the breast—after receiving surgery, radiation, or chemotherapy. The recommended regimen for AET ...
LOS ANGELES – In recent years, Black patients with triple-negative breast cancer (TNBC) received immunotherapy at significantly lower rates than white patients, according to results presented at the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held September 21-24, 2024.
Black women are disproportionately affected by TNBC, an aggressive subtype of breast cancer defined by the lack of three cell surface receptors. The absence of these receptors means that patients with TNBC are ineligible for many of the molecularly targeted therapies used to treat other breast cancer subtypes, explained ...
LOS ANGELES – The Affordable Care Act (ACA) has led to increased guideline-concordant care for colon cancer among non-white patients, patients from rural areas, and patients from the most deprived neighborhoods in Pennsylvania, according to results presented at the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held September 21-24, 2024.
“The ACA was the largest change to the health insurance system in the United States since the introduction of Medicare and Medicaid ...
A study of stigma against LGBTQ (lesbian, gay, bisexual, transgender and queer) people in British Society has shown that there is less stigma against these groups that might be expected from social and media perceptions. The same study looked at stigma against people with mental health problems and discovered that they continue to experience higher levels of stigma. This work will be presented at the ECNP conference in Milan. This is an advance press release see note below.
Researcher Professor Karen Ersche (University of Cambridge) said, “Our aim was to look at the level of stigma against LGBTQ people in British society, and also to look at stigma ...
Cells are highly controlled spaces that rely on every protein being in the right place. Many diseases, including cancers and neurodegenerative disorders, are associated with misplaced proteins. In some cancers, for instance, a protein that normally stands watch over DNA replicating in the nucleus is sent far from the DNA it is meant to monitor, allowing cancers to grow.
Steven Banik, assistant professor of chemistry in the School of Humanities and Sciences and institute scholar at Sarafan ChEM-H at Stanford University, and his lab have developed a new method to help force misplaced proteins back to their proper homes within cells. The method ...
In a study published July 29 in Advanced Materials, University of Texas at Dallas researchers found that X-rays of the kidneys using gold nanoparticles as a contrast agent might be more accurate in detecting kidney disease than standard laboratory blood tests. Based on their study in mice, they also found that caution may be warranted in employing renal-clearable nanomedicines to patients with compromised kidneys.
Before administering renal-clearable drugs, doctors routinely check a patient’s kidney function by testing their ...
The Texas A&M University School of Public Health and USAging have been awarded the 2024 Immunization Neighborhood Champion Award by the U.S. Centers for Disease Control’s National Adult and Influenza Immunization Summit. Matthew Lee Smith, PhD, professor at the School of Public Health, leads the school’s involvement as a founding member of USAging’s Aging and Disability Vaccination Collaborative (ADVC).
Announced as respiratory illness season is ramping up in the United States, this honor recognizes Smith’s work in support of ADVC’s efforts ...
EL PASO, Texas (Sept. 20, 2024) – The University of Texas at El Paso today announced new collaborations with the Department of Defense (DoD) and the National Security Agency (NSA) that support research and training to strengthen the nation’s leadership in semiconductor, or microchips, technology.
NSA, the signals intelligence and cybersecurity agency for the United States, also recently named UTEP as an NSA Center of Academic Excellence in Cybersecurity Research, making UTEP one of only 11 universities nationwide to hold all three ...
Homicide is a leading cause of death among people 19 and younger in the United States, and firearms are used in a large proportion of these crimes. Although the homicide rate for this population declined in the 1990s and 2000s, it has increased every year since 2013, with a large spike during the COVID-19 pandemic.
Now, new research by Hannah Rochford, PhD, an assistant professor with the Texas A&M University School of Public Health, and two colleagues from the University of Iowa, provides insight into the characteristics of ...
